Bladder cancer makes up about 4% of cancers, most commonly affecting people 55 and older. While rates for bladder cancer are ...

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.

Researchers discovered that antiviral enzymes induce early mutations in bladder cancer, and standard chemotherapy causes ...

The study focused on urothelial carcinoma, the most common form of bladder cancer, and used advanced whole-genome sequencing ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

Adding immunotherapy to platinum chemotherapy can improve outcomes of urothelial carcinoma, but that may depend on the platinum agent used.

Opens in a new tab or window In the U.S., the economic burden associated with the latest first-line treatments for locally advanced or metastatic urothelial carcinoma (la/mUC) is significant.

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma (URGN – Research Report), with a ...

On October 10, 2024, Boxer Capital, LLC made a significant addition to its investment portfolio by acquiring 85,939 shares of Tyra Biosciences Inc (NASDAQ:TYRA). This transaction has increased the ...

This is the first comprehensive immunohistochemical analysis of the expression of several class I HDAC proteins (1, 2 and 3) in urothelial carcinoma. In our study, we found all three isoforms in a ...

Patients with the mesenchymal-like subtype had both significantly lower response rate and shorter survival, while the luminal-like subtypes (urothelial-like and genomically unstable) displayed the ...